logo

Nektar Therapeutics (NKTR)



Trade NKTR now with
  Date
  Headline
11/12/2020 8:01:28 AM William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
11/5/2020 4:18:04 PM Nektar Therapeutics Q3 Loss/Shr $0.61 Vs $0.56 Last Year
10/27/2020 7:33:58 AM Nektar Therapeutics Received FDA Clearance For IND Application For Investigational IL-2 Pathway Agent, Bempegaldesleukin
8/12/2020 8:07:29 AM Vaccibody And Nektar Therapeutics Announce First Patient Dosed In Phase 1/2a Study Arm Evaluating VB10.NEO With NKTR-214
8/6/2020 4:19:35 PM Nektar Q2 Loss/Shr $0.45 Vs Loss $0.63 Last Year
6/8/2020 8:06:23 AM William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
5/22/2020 8:32:54 AM Nektar Reports Publication Of Results From Phase 1 Dose-Escalation Study For Bempegaldesleukin Plus Nivolumab
2/28/2020 8:12:37 AM William Blair Is Cutting Nektar Therapeutics (NKTR) FY22 Rev. Estimate To 108 M From 170 M
2/28/2020 8:12:22 AM William Blair Is Cutting Nektar Therapeutics (NKTR) FY21 Rev. Estimate To 107 M From 159 M
2/28/2020 8:12:07 AM William Blair Is Increasing Nektar Therapeutics (NKTR) FY20 Rev. Estimate To 144 M From 133 M
2/28/2020 8:11:41 AM William Blair Is Raising Nektar Therapeutics (NKTR) FY22 Estimate To -3.55 From -3.64
2/28/2020 8:11:25 AM William Blair Is Raising Nektar Therapeutics (NKTR) FY21 Estimate To -3.18 From -3.22
2/28/2020 8:11:07 AM William Blair Is Increasing Nektar Therapeutics (NKTR) FY20 Estimate To -2.96 From -3.00
2/28/2020 7:57:41 AM William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform